We are international

Myeloma Minute
August 1, 2013
August 1, 2013
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF

Watch this week's episode
of #AskDr.Durie, the IMF's weekly web series

Upcoming Events

August 9-10, 2013
Chicago Patient & Family Seminar
Chicago, Illinois

August 23-24, 2013
Philadelphia Patient & Family Seminar
Philadelphia, Pennsylvania


Saturday, October 12, 2013
St. Louis Regional Community Workshop
St. Louis, Missouri

Study Examines Early Intervention in High-Risk Smoldering Myeloma Patients
A highly-awaited multiple myeloma research study published this week in The New England Journal of Medicine (NEJM) highlights the benefits of early intervention in high-risk smoldering myeloma. "The results of this excellent and important clinical trial tie directly into our Black Swan Research Initiative," said Dr. Brian Durie, Chairman of the International Myeloma Foundation. The study, conducted by researchers in Spain, concluded that in patients with high-risk smoldering myeloma, early intervention and maintenance with a Revlimid-based regimen significantly delayed the time to progression to symptomatic disease, and resulted in an overall survival benefit. "The challenge now is to identify which patients stand to benefit from these findings," said Dr. Durie. "Patients with early myeloma hold the key to understanding the progression of myeloma, and through BSRI, will help us optimize treatment for patients at all stages of the disease." READ MORE
Dr. Robert Kyle Recognized by OncLive as One of the 'Giants of Cancer Care'
Dr. Robert Kyle, for whom the IMF's annual Robert A. Kyle Lifetime Achievement Award is named, was recognized as one of the 'Giants of Cancer Care' by OncLive magazine. The inaugural awards, which were given on Friday, July 26, recognized 12 individuals "who have achieved landmark successes within the field of oncology." The award celebrates "pioneers, innovators, and future generations of leaders who have been selected by their peers for their remarkable achievements in oncology research and clinical practice." Among Dr. Kyle's accomplishments: discovering two significant conditions, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, laying the groundwork to understand myeloma disease progression. Congratulations, Dr. Kyle! READ MORE
Clinical Trial Seeks Myeloma Patients Up to Age 65
A research study led by Paul Richardson, M.D., is looking to explore the drug combination of lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation in patients up to age 65 to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma. The objective is to determine if, in the era of novel drugs, high dose therapy (HDT) is still necessary in the initial management of multiple myeloma in younger patients. READ MORE HERE
Israeli Association for Myeloma Patients Petitions for Access to Novel Therapies
AMEN Foundation, the Israeli Association of Myeloma Patients, is petitioning the Israeli government to have pomalidomide and carfilzomib included as treatment options available to the country's citizens through their health "baskets." About 250 new patients are diagnosed in Israel each year, and the disease affects approximately 2,000 patients and their families. "Having access to a variety of myeloma treatments is critical for patients who need to have options when the treatment they are using stops working," said Arin Assero, IMF Vice President of Global Advocacy. In June, AMEN participated in the IMF's Global Leaders Summit, which brought blood cancer patient advocacy organizations together from around the world to discuss effective ways to work together on behalf of patients. Please support our friends at AMEN Foundation by signing the PETITION!

Join Our Mailing List

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe

 related articles